PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV

Severe Acute Respiratory Syndrome (SARS) is a deadly infectious disease caused by SARS Coronavirus (SARS-CoV). Inactivated SARS-CoV has been explored as a vaccine against SARS-CoV. However, safe and potent adjuvants, especially with more efficient and economical needle-free vaccination are always ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Gai, Wei-wei, Zhang, Yan, Zhou, Di-han, Chen, Yao-qing, Yang, Jing-yi, Yan, Hui-min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SP Wuhan Institute of Virology, CAS 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091335/
https://www.ncbi.nlm.nih.gov/pubmed/21468931
http://dx.doi.org/10.1007/s12250-011-3183-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091335/
https://www.ncbi.nlm.nih.gov/pubmed/21468931
http://dx.doi.org/10.1007/s12250-011-3183-z

Ejemplares similares